Back to Blog

Presibo Selected for Orange Corners Nigeria Cohort 14 Incubation Program

October 10, 2025
PA
By Presibo Admin
Presibo selected for Orange Corners Nigeria Cohort 14

Lagos, Nigeria — We are delighted to share that Presibo has been officially selected to join Cohort 14 of the Orange Corners Nigeria (OCN) incubation program. Out of thousands of applicants across Nigeria, Presibo was chosen for its innovative approach to addressing chronic care management and local health infrastructure.

Orange Corners Nigeria is an initiative of the Kingdom of the Netherlands, implemented by the FATE Foundation in Nigeria. The program provides young entrepreneurs with a six-month intensive acceleration training, business mentoring, workspace access, and potential seed funding opportunities through the Orange Corners Innovation Fund (OCIF).

"Being selected for Orange Corners Cohort 14 validates our dedication to fixing the highly fragmented healthcare management landscape in Nigeria. FATE Foundation's legacy of nurturing business leaders coupled with support from the Dutch government will assist us in scaling operations." — Jerry Nwobodo, Founder & CEO of Presibo

Building Resilience in African Healthcare

The OCN incubation program focuses heavily on sustainable growth models, market validation, and investment readiness. For Presibo, this comes at a critical execution stage. Having launched our mobile application and completed initial terminal testing earlier this year, our focus is now on structured B2B partnerships with local clinics and pharmacies.

Through OCN's mentorship network, our leadership team will collaborate with experienced medical, regulatory, and corporate executives to navigate the complex healthcare compliance landscape in Nigeria, ensuring our clinical AI and data systems operate under top-tier governance protocols.

Key Objectives for the Incubation Period

During the next six months, Presibo will target several strategic milestones:

We are grateful for this selection and look forward to representing Cohort 14 with high-impact, clinical-grade innovation that transforms chronic care across Nigeria.